| Literature DB >> 35566233 |
Aliya Nur Hasanah1,2, Ike Susanti1, Mutakin Mutakin1.
Abstract
Beta-blockers are antihypertensive drugs and can be abused by athletes in some sport competitions; it is therefore necessary to monitor beta-blocker levels in biological samples. In addition, beta-blocker levels in environmental samples need to be monitored to determine whether there are contaminants from the activities of the pharmaceutical industry. Several extraction methods have been developed to separate beta-blocker drugs in a sample, one of which is molecularly imprinted polymer solid-phase extraction (MIP-SPE). MIPs have some advantages, including good selectivity, high affinity, ease of synthesis, and low cost. This review provides an overview of the polymerization methods for synthesizing MIPs of beta-blocker groups. The methods that are still widely used to synthesize MIPs for beta-blockers are the bulk polymerization method and the precipitation polymerization method. MIPs for beta-blockers still need further development, especially since many types of beta-blockers have not been used as templates in the MIP synthesis process and modification of the MIP sorbent is required, to obtain high throughput analysis.Entities:
Keywords: beta-blocker; molecularly imprinting; separation; solid phase extraction
Mesh:
Substances:
Year: 2022 PMID: 35566233 PMCID: PMC9104958 DOI: 10.3390/molecules27092880
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
List of Cmax of various beta-blockers in plasma.
| Name of Drug | Doses (mg) | Cmax (ng/mL) | Tmax (h) | Ref |
|---|---|---|---|---|
| Atenolol | 100 | 537.1 + 112.7 | 3.4 + 1.0 | [ |
| Carvedilol | 8 | 6.93 | 5.98 | [ |
| 128 | 77.94 | 6.02 | ||
| Bisoprolol | 5 | 31 | 3 | [ |
| Metoprolol | 80 | 100 | 1 | [ |
| Labetalol | 200 | 182 ± 57 (fasting state); 180 ± 33 (after food) | 1.42 ± 0.28 (fasting state); 2.08 ± 0.15 (after food) | [ |
| Oxprenolol | 80 | 22.5 | 1.21 | [ |
| Propranolol | 40 | 24.9 | 2.1 | [ |
Note: Cmax: measured peak plasma concentration; Tmax: time to reach peak concentration.
Methods for the extraction of beta-blockers in different matrices.
| Analyte | Sample | Extraction Method | Method | Linearities | LOD and LOQ | Ref |
|---|---|---|---|---|---|---|
| Atenolol | Plasma | LLE | HPLC with fluorescence detector | 10–1000 ng/mL | NM | [ |
| Atenolol | Plasma | LLE | HPLC with fluorescence detector | 10–1000 ng/mL | NM | [ |
| Atenolol | Urine | LLE | HPLC with fluorescence detector | 5–150 ng/mL | 1.5 ng/mL; 5.0 ng/mL | [ |
| Propranolol | Plasma | Protein precipitation | HPLC with DAD detector | 20–280 ng/mL | NM | [ |
| Metoprolol | Serum | Protein precipitation | HPLC-MS/MS | 5–250 ng/mL | NM | [ |
| Bisoprolol | 1–250 ng/mL | |||||
| Metoprolol | Urine and plasma | Continuous flow membrane microextraction | HPLC | 5–700 µg/mL | 1.0 ng/mL (LOD) | [ |
| Propranolol | 3–1000 µg/mL | 0.5 ng/mL (LOD) | ||||
| Carvedilol | Urine, plasma, and tablet | Ionic liquid microextraction | Spectrofluorometer | 0–250 μg/L | 1.7 μg/L (LOD) | [ |
| Celiprolol | Plasma | SPE | HPLC with fluorescence detector | 1–1000 ng/L | NM | [ |
| Carvedilol | Serum | Stir bar sorptive extraction | HPLC with UV detector | 1.0–120.0 ng mL | 0.3 and 1.0 ng/mL | [ |
| 23 compounds of β-Blockers | Animal food | SPE coupled with a clean-up step using methanol | HPLC coupled with linear ion trap mass spectrometry | 5–200 μg/L | NM | [ |
| Bisoprolol | Wastewater treatment plants | SPE | Liquid chromatography coupled with mass spectrometry (LC-MS/MS) | 1–100 ng/mL | 0.34–7.37 ng/L (LOQ) | [ |
| Nadolol | ||||||
| Betaxolol | ||||||
| Atenolol | ||||||
| Propranolol | ||||||
| Pindolol | ||||||
| Atenolol | Urine and plasma | AALLME using floating organic droplet solidification | UV-Vis spectrophotometry | 0.30–6.00 μg/mL | 0.30 μg/mL (LOQ) | [ |
| Propranolol | 0.30–1.40 μg/mL | 0.26 μg/mL (LOQ) | ||||
| Carvedilol | 0.30–2.00 μg/mL | 0.30 μg/mL (LOQ) | ||||
| Timolol | Plasma | Cation-exchange SPE | Ion-pairing UPLC | 5–300 ng/mL | 1.7 ng/mL (LLOD); 5.0 ng/mL (LLOQ) | [ |
| Metoprolol | Urine | A salting-out assisted liquid–liquid extraction (SALLE) | Hydrophilic interaction liquid chromatography-ultraviolet detection (HILIC-UV) | 0.2–8.0 µg/mL | NM | [ |
| Propranolol | 0.1–4.0 µg/mL | |||||
| Carvedilol | 0.1–4.0 µg/mL | |||||
| 5-hydroxy carvedilol | 0.2–8.0 µg/mL | |||||
| O-desmethyl carvedilol | 0.1–4.0 µg/mL | |||||
| α-hydroxy metoprolol | 0.2–8.0 µg/mL | |||||
| O-desmethyl metoprolol | 0.2–8.0 µg/mL | |||||
| 5-hydroxy propranolol | 0.1–4.0 µg/mL | |||||
| Atenolol, metoprolol, esmolol, pindolol, and arotinolol | River water, influent wastewater (IWW), and effluent wastewater (EWW) | Magnetic solid phase extraction (MSPE) | Chiral LC-MS/MS | 5–500 ng/mL | 0.50–1.45 ng/L, 1.63–3.75 ng/L | [ |
| 21 β-blockers and 6 metabolites | Milk powder | Extracted using acetonitrile and purified with SPE | HPLC coupled with quadrupole orbitrap high-resolution mass spectrometry (HPLC-Q-Orbitrap HRMS) | 0.5–500 µg/kg | 0.2–1.5 µg/kg (LOD), 0.5–5.0 µg/kg (LOQ) | [ |
| Atenolol | Human bone | SPE | Gas chromatography–mass spectrometry | 0.1–150 ng/mg | 0.1 ng/mL (LOD) | [ |
| Bisoprolol | 0–15 ng/mg | 0.3 ng/mL (LOD) | ||||
| Atenolol | Rabbit plasma | SPE | Derivatization with hydrazonoyl chloride compound (UOSA54), determined using liquid chromatography–tandem mass spectrometry (LC-MS) | 0.2–20.0 ng/mL | 0.08 ng/mL, 0.20 ng/mL | [ |
| Metoprolol | ||||||
| Bisoprolol | 0.2–18.0 ng/mL | 0.05 ng/mL, 0.20 ng/mL | ||||
| Propranolol | 0.1–15.0 ng/mL | 0.03 ng/mL, 0.10 ng/mL | ||||
| Betaxolol | 0.2–25.0 ng/mL | 0.06 ng/mL, 0.25 ng/mL | ||||
| Metoprolol | Water | Vortex-assisted liquid–liquid microextraction based on in situ formation of a novel hydrophobic natural deep eutectic solvent (NADES-VA-LLME) | HPLC | 1–100 μg/L | 0.2 μg/L, 0.6 μg/L | [ |
| Metoprolol | Plasma and urine | Magnetic dispersive micro-solid phase extraction | HPLC | 5–10,000 ng/mL | 0.8 ng/mL; 5 ng/mL | [ |
| Atenolol | 50–5000 ng/mL | 10 ng/mL; 50 ng/mL | ||||
| Propranolol | 10–5000 ng/mL | 2 ng/mL; 10 ng/mL | ||||
| Atenolol | Plasma | LLME using a hydrophobic deep eutectic solvent | Gas chromatography-mass spectrometry (GC-MS) | 0.064–5000 ng/mL | 0.195 ng/mL, 0.645 ng/mL | [ |
| Propranolol | 0.043–5000 ng/mL | 0.130 ng/mL, 0.435 ng/mL | ||||
| Metoprolol | 0.069–5000 ng/mL | 0.205 ng/mL, 0.692 ng/mL |
NM: not mentioned in the article; LOD: Limit of Detection; LOQ: Limit of Quantification; LLE: liquid–liquid extraction; HPLC: High-Performance Liquid Chromatography; DAD: Diode-Array Detection; HPLC-MS/MS: High-performance Liquid Chromatography–tandem Mass Spectrometry; AALLME: Air-Assisted Liquid–Liquid Microextraction; UPLC: Ultra-Performance Liquid Chromatography; SPE: Solid Phase Extraction.
Synthesis methods of molecularly imprinted polymers that have been developed for beta-blocker drugs.
| Beta-Blocker Drug | Synthesis Method |
|---|---|
| Atenolol | Bulk polymerization |
| Precipitation polymerization | |
| Carvedilol | Bulk polymerization |
| Surface imprinted polymerization: magnetic molecularly imprinted polymer (MMIP) | |
| Pindolol | Bulk polymerization |
| Sotalol | Bulk polymerization |
| Surface imprinted polymerization: multiwalled carbon nanotubes based magnetic molecularly imprinted polymer (MWCNT-MMIP) | |
| Propranolol | Precipitation polymerization |
| In situ polymerization: thin layer MIPs in multiwell membrane filter plates | |
| In situ polymerization: graphene oxide (GO)/MIP coated stir bar sorbent | |
| Monolithic imprinted polymerization | |
| Oxprenolol | Precipitation polymerization |
Studies involving the synthesis of MIPs using the bulk polymerization method.
| Template | Monomer | Cross-Linker | Porogenic Solvent | Initiator | Q (mg/g) | IF | % Recovery | Application | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Atenolol | Methacrylic acid | EGDMA | Butanol | Benzoyl peroxide | 7.804 | 2.87 ± 0.2 | NM | NM | [ |
| Atenolol | Methacrylic acid | EGDMA | Propanol | Benzoyl peroxide | 0.1043 | 2.872 | 66.54% | Extraction of atenolol in serum sample | [ |
| Butanol | 7.804 | 2.868 | 32.22% | ||||||
| Atenolol | Acrylic acid | EGDMA | Dichloro- ethane | Benzoyl peroxide | 3.77 | 4.18 | 74.5–75.1% | Selective removal of atenolol in a human urine sample | [ |
| Carvedilol | Methacrylic acid | EGDMA | Chloroform | 4,4′-Azobis(4-cyanovaleric acid) | NM | NM | Around 100% | Used as adsorbent of PT-MIP-MS to extract carvedilol enantiomer in human urine | [ |
| Pindolol | Itaconic acid | EGDMA | Acetonitrile | AIBN | 125.76 * | 2.27 | NM | NM | [ |
| 4-vinyl pyridine | 9.93 * | 1.89 | |||||||
| Acrylonitrile | 56.732 * | 1.12 | |||||||
| Sotalol | Acrylamide | EGDMA | Dimethylformamide | AIBN | 20.08 | NM | 97.4–102.5 | Used as SPE sorbent for extraction of sotalol in urine sample | [ |
* The total number of binding sites μmol/g. NM: not mentioned in the article; Q: adsorption capacity; IF: Imprinting Factor; EGDMA: Ethylene Glycol Dimethacrylate; AIBN: Azobisisobutyronitrile; PT-MIP-SPE: Pipette-Tip Molecularly Imprinted Polymer-Solid Phase Extraction.
Figure 1Radical polymerization: 1. Initiation; 2. Propagation; 3. Termination.
Several studies on synthesis of MIPs using the precipitation polymerization method.
| Template | Monomer | Cross-Linker | Initiator | Porogenic Solvent | Q (mg/g) | IF | % Recovery | Application | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Atenolol | Itaconic acid | EGDMA | Benzoyl peroxide | Methanol: acetonitrile | 4.250 | 11.02 (sample spiked with atenolol) | 93.65 ± 1.29% | Extraction of atenolol in serum sample | [ |
| Itaconic acid | Methanol | 0.269 | NM | NM | |||||
| Atenolol | Methacrylic acid | EGDMA | Benzoyl peroxide | Propanol | 0.0804 | 11.721 | 74.64% | Extraction of atenolol in serum sample | [ |
| Butanol | 2.950 | 4.160 | 10.86% | ||||||
| Atenolol | Methacrylic acid | EGDMA | Benzoyl peroxide | Butanol | 2.950 | 4.16 ± 2.1 | NM | NM | [ |
| Atenolol | Methyl methacrylate | EGDMA | Benzoyl peroxide | Butanol | 2.166 | 5.967 | NM | NM | [ |
| Oxprenolol | Methacrylic acid | EGDMA | AIBN | Acetonitrile | 82.6 | NM | NM | Online MIP-SPE couple liquid chromatography and spectrometry conditions | [ |
| (R,S) Propranolol | 4,4′-Azobis(4-cyanovaleric) acid (functionalized initiator) | Trimethylolpropane trimethacrylate (TRIM) | Acetonitrile | 25.51 | NM | NM | Not mentioned in article, may be used to separate the chiral molecule in pharmaceutical product or others | [ | |
| (S)-Propranolol | 2.03 | ||||||||
NM: not mentioned in the article; Q: adsorption capacity; IF: Imprinting Factor; EGDMA: Ethylene Glycol Dimethacrylate; AIBN: Azobisisobutyronitrile; MIP-SPE: Molecularly Imprinted Polymer-Solid Phase Extraction.
Comparison of bulk and precipitation polymerization method in synthesis of MIP with atenolol as the template.
| Template | Method | M | C | P | I | Q (mg/g) | IF | Ref |
|---|---|---|---|---|---|---|---|---|
| Atenolol | Bulk | Methacrylic acid | EGDMA | Butanol | Benzoyl peroxide | 7.804 | 2.87 ± 0.2 | [ |
| Precipitation | 2.950 | 4.16 ± 2.1 | ||||||
| Atenolol | Bulk | Methacrylic acid | EGDMA | Butanol | Benzoyl peroxide | 7.804 | 2.868 | [ |
| Precipitation | 2.950 | 4.160 | ||||||
| Atenolol | Bulk | Methacrylic acid | EGDMA | Propanol | Benzoyl peroxide | 0.1043 | 2.872 | |
| Precipitation | 0.0804 | 11.721 |
M: functional monomer; C: cross-linker; P: porogenic solvent; I: initiator; m: homogeneity index of adsorption site; Q: adsorption capacity; IF: Imprinting Factor; EGDMA: Ethylene Glycol Dimethacrylate.
Figure 2Scheme of synthesis of multiwalled carbon nanotubes based magnetic molecularly imprinted polymer (MWCNT-MMIPs).
Figure 3Procedure for extraction using ultrasonic-assisted dispersive solid-phase microextraction method (UA@DSPME).
Figure 4Schematic illustration of magnetic molecularly imprinted polymer (MMIP) synthesis.
Figure 5Multiwell membrane filter plates modified with MIPs.
Advantages and disadvantages of different polymerization methods.
| Polymerization Methods | Advantages | Disadvantages |
|---|---|---|
| Bulk polymerization |
Using a small amount of porogenic solvent. The size of MIP can be easily controlled. |
Time-consuming because of the grinding process. Irregularly shaped sorbent Damage the binding site cavity and reduce the recognition ability because of the grinding process. |
| Precipitation polymerization |
The regular shape of MIPs. Does not require grinding process. Easy procedure and less time consuming. |
It needs a high amount of solvent. Precipitation occurs only when the polymer chains are large enough to be insoluble in the reaction mixture. |
| Surface imprinted polymerization |
Uniform particle size. High specific surface. Better recognition increases the binding capacity. The fast mass transfer rate. |
Needs a lot of steps in the synthesis. |
| In situ polymerization |
Does not require crushing, grinding, and sieving to produce. The imprinted polymer is printed directly on the surface of the transducer or is immobilized after the synthesis process. |
Removing template molecules often requires harsh conditions. |